Ardelyx (ARDX) vs Rigel Pharmaceuticals (RIGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Rigel Pharmaceuticals (RIGL) has outperformed Ardelyx (ARDX) over the past year, gaining 62.7% versus a loss of 36.9%. Over five years, ARDX leads with a +201.9% price change compared with +42.0% for RIGL. Rigel Pharmaceuticals is the larger company by market cap ($875.9 million vs $828.8 million), about 1.1 times the size.
On valuation, Rigel Pharmaceuticals trades at a lower forward P/E (9.5x vs 11.1x for Ardelyx).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARDX | RIGL |
|---|---|---|
| Share price | $3.21 | $46.89 |
| Market cap | $828.78M | $875.90M |
| 1-day change | -1.53% | -2.29% |
| YTD return | -44.08% | +12.05% |
| 1-year return | -36.94% | +62.68% |
| 5-year return | +201.85% | +41.98% |
| P/E ratio (TTM) | — | 2.78 |
| Forward P/E | 11.05 | 9.49 |
| EPS (TTM) | $-0.23 | $16.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $52.24 |
| 52-week low | $3.18 | $24.95 |
| Distance from 52-week high | -61.79% | -10.24% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +301.87% | +34.36% |
| Average volume | 4.10M | 290.66K |
| Shares outstanding | 258.19M | 18.68M |
| Employees | 489 | 172 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RIGL has outperformed ARDX by 99.6 percentage points over the past year.
About Ardelyx
ARDX stock →Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 489 employees
About Rigel Pharmaceuticals
RIGL stock →Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 172 employees
ARDX vs RIGL FAQ
Which is bigger, Ardelyx or Rigel Pharmaceuticals?
Rigel Pharmaceuticals (RIGL) is larger, with a market capitalization of $875.90M compared with $828.78M for Ardelyx (ARDX).
Which stock has performed better over the past year, ARDX or RIGL?
RIGL returned +62.68% over the past 12 months, compared with -36.94% for ARDX (price return, excluding dividends). Past performance does not predict future results.
Are Ardelyx and Rigel Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.